Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

Bayer subsidiary granted FDA’s fast track designation for new congestive heart failure treatment
AskBio, acquired by Bayer for more than $2 billion in 2020, is enrolling patients for a new clinical trial focused on the therapy's effectiveness in adult patients with non-ischemic cardiomyopathy and heart failure.
FDA grants fast track designation to new drug for Friedreich's ataxia cardiomyopathy
The new gene therapy candidate is now one step closer to being approved by the FDA.
PHOTO GALLERY: Highlights from ACC.24 in Atlanta
ACC.24, the American College of Cardiology's annual meeting in Atlanta, featured the latest in cardiovascular research and technologies. Representatives from Cardiovascular Business were there in person to take in the excitement.
FDA grants anticoagulant its orphan drug designation for treating patients with implanted devices
The anticoagulant was originally developed for patients with end-stage renal disease and atrial fibrillation.
Weight loss drug semaglutide benefits obese patients presenting with HFpEF, type 2 diabetes
The new research, based on data from more than 600 patients, was presented at ACC.24 in Atlanta and published in the New England Journal of Medicine. Semaglutide is sold by Novo Nordisk under the brand name Wegovy.

Bayer subsidiary granted FDA’s fast track designation for new congestive heart failure treatment

AskBio, acquired by Bayer for more than $2 billion in 2020, is enrolling patients for a new clinical trial focused on the therapy's effectiveness in adult patients with non-ischemic cardiomyopathy and heart failure.

April 19, 2024

FDA grants fast track designation to new drug for Friedreich's ataxia cardiomyopathy

The new gene therapy candidate is now one step closer to being approved by the FDA.

April 17, 2024

The V-Wave intra-atrial shunt to treat heart failure on display on the expo floor at ACC.24. The device was used in one of the late breaking trials at ACC. DF 3

PHOTO GALLERY: Highlights from ACC.24 in Atlanta

ACC.24, the American College of Cardiology's annual meeting in Atlanta, featured the latest in cardiovascular research and technologies. Representatives from Cardiovascular Business were there in person to take in the excitement.

April 16, 2024

FDA grants anticoagulant its orphan drug designation for treating patients with implanted devices

The anticoagulant was originally developed for patients with end-stage renal disease and atrial fibrillation.

April 9, 2024

Weight loss drug semaglutide benefits obese patients presenting with HFpEF, type 2 diabetes

The new research, based on data from more than 600 patients, was presented at ACC.24 in Atlanta and published in the New England Journal of Medicine. Semaglutide is sold by Novo Nordisk under the brand name Wegovy.

April 7, 2024

Novo Nordisk to acquire biotech company working on new heart failure drug for $1.1B

Cardior Pharmaceuticals in Germany has been developing a new compound it says can “halt and partially reverse cellular pathology” in heart failure patients.

March 25, 2024

Medicare will now cover weight loss drug semaglutide if taken for heart benefits

The news represents a meaningful policy shift for CMS. In the past, Medicare prescription drug plans have not covered medications designed to help patients lose weight.

March 22, 2024

COVID-19 vaccine vaccination myocarditis heart damage inflammation RSNA imaging radiology cardiology

‘Highly effective’: COVID-19 vaccines reduced risk of heart failure, other cardiovascular complications after infection

Researchers explored data from more than 20 million adults for the new study, tracking both short- and long-term outcomes.

March 20, 2024

Around the web

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business

What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."